Accessibility Menu
Faron Pharmaceuticals Oy logo

Faron Pharmaceuticals Oy(LSE) FARN

Current Price£0.40
Market Cap£81.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-82%
5 Year-88%
1 Year-79%
1 Month-7%
Faron Pharmaceuticals Oy last closing stock price
MetricPriceDate
Last closeGBX 41.002026-07-22
Faron Pharmaceuticals Oy stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.38%GBX 42.002026-07-15
1 month-6.82%GBX 44.002026-06-22
3 month-5.53%GBX 43.402026-04-23
Year to date-77.22%GBX 180.002025-12-31
1 year-79.29%GBX 198.002025-07-22
3 year-81.38%GBX 220.152023-07-21
5 year-87.51%GBX 328.152021-07-23
Since inception-81.95%GBX 2.242015-11-17

Faron Pharmaceuticals Oy Financials at a Glance

Market Cap

£81.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€0.00

Net Income (TTM)

-€7.87M

EPS (TTM)

-£0.21

P/E Ratio

-1.98

Dividend

£0.00

Beta (Volatility)

0.03 (Low)

Price

£0.40

Volume

20

Open

£0.41

Previous Close

£0.40

Daily Range

£0.40 - £0.42

52-Week Range

£0.38 - £2.34

Estimated Earnings Date

Aug 26, 2026

FARN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy is a clinical-stage biotechnology company based in Turku, Finland, focused on developing innovative pharmaceutical solutions. The company specializes in immune modulation to address significant unmet medical needs, with a pipeline that includes therapies for immuno-oncology, organ safeguarding, and regenerative medicine.

Products and Services
  • Traumakine: An intravenous interferon beta-1a treatment for ARDS and COVID-19
  • Bexmarilimab: A precision cancer immunotherapy targeting solid tumors and hematological malignancies
  • Haematokine: A new AOC3 inhibitor for treating hematological malignancies
Growth Outlook
  • Strong focus on immuno-oncology and regenerative medicine markets
  • Pipeline includes multiple candidates addressing critical health issues
  • Potential for partnerships to enhance research and development capabilities
Financial Highlights
  • Recent quarterly net income of -7.83 million EUR, reflecting ongoing R&D investments
  • Trailing twelve months (TTM) revenue of 0, indicating early-stage development
  • Cash and cash equivalents of 12.31 million EUR as of the latest quarter
Faron Pharmaceuticals Oy is positioned in a dynamic sector with a focus on addressing critical health challenges through innovative therapies. The company's leading candidates, such as Traumakine and Bexmarilimab, are under investigation for significant medical conditions, which could lead to substantial market opportunities. The absence of revenue at this stage is typical for clinical-stage companies, as investments are primarily directed towards research and development. The financial position, with a notable cash reserve, supports ongoing projects and potential future growth. As the biotechnology landscape evolves, Faron's strategic focus on immune modulation and partnerships may enhance its market presence and drive long-term value.
AI Generated • Jul 17, 2026

Industry

Biotechnology

Sector

Health Care

Employees

33

CEO

Juho Markku Jalkanen, PhD, MD

Website

www.faron.com

Headquarters

Turku, FP 20520, FI

FARN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

45.13%

Return on Capital

-328.32%

Return on Assets

-45.68%

Earnings Yield

-50.51%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£81.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

199.51M

Volume

20

Avg. Volume

69.14K

Financials (TTM)

Gross Profit

-€174.94K

Operating Income

-€8.38M

EBITDA

-€8.20M

Operating Cash Flow

-€34.41M

Capital Expenditure

€0.00

Free Cash Flow

-€34.41M

Cash & ST Invst.

€12.31M

Total Debt

€24.67M

Faron Pharmaceuticals Oy Performance Analysis

Faron Pharmaceuticals Oy annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 0N/A
20232023-12-31EUR 0N/A
20242024-12-31EUR 0N/A
20252025-12-31EUR 0N/A
Faron Pharmaceuticals Oy sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Faron Pharmaceuticals Oy annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -0.3523.6%
20232023-12-31EUR -0.33-6.8%
20242024-12-31EUR -0.24-27.6%
20252025-12-31EUR -0.21-12.4%
Faron Pharmaceuticals Oy sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3099.9%
Q42024-12-3145.9%
Q22025-06-30-67.1%
Q42025-12-3120.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

€0.00

N/A

Gross Profit

-€174.94K

N/A

Gross Margin

0.00%

N/A

Market Cap

£81.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£2.48M

N/A

Employees

33

N/A

Net Income

-€7.83M

+54.5%

EBITDA

-€8.18M

+48.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

€12.31M

+79.1%

Total Debt

€24.67M

+88.2%

Accounts Receivable

€512.83K

N/A

Inventory

€0.00

N/A

Long Term Debt

€14.27M

+50.7%

Short Term Debt

€10.40M

+185.9%

Return on Assets

-45.68%

N/A

Return on Invested Capital

4.91%

N/A

Free Cash Flow

-€11.44M

-99658.3%

Operating Cash Flow

-€11.44M

-99658.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BVXP.LBioventix PLC
£15.50+0.00%
SCLP.LScancell Holdings plc
£0.10-18.67%
HEMO.LHemogenyx Pharmaceuticals Plc
£7.30-3.88%
SAR.LSareum Holdings plc
£0.24+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.00+0.04%
AALAmerican Airlines Group
$14.79-0.03%
PATHUiPath
$10.70-0.11%
NOKNokia
$10.28-0.03%

Questions About FARN

What is the current price of Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy is trading at £0.40 per share.

What is the 52-week range for Faron Pharmaceuticals Oy?

Over the past 52 weeks, Faron Pharmaceuticals Oy has traded between £0.38 and £2.34.

How much debt does Faron Pharmaceuticals Oy have?

As of the most recent reporting period, Faron Pharmaceuticals Oy reported total debt of €21.55M.

How much cash does Faron Pharmaceuticals Oy have on hand?

Faron Pharmaceuticals Oy reported €10.75M in cash and cash equivalents in its most recent financial results.

What is Faron Pharmaceuticals Oy’s dividend yield?

Faron Pharmaceuticals Oy does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services